Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

In the second quarter, attributable net income increased by 45 percent to 1.5 billion yuan from 1.067 billion yuan in the ...

Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

In this week’s edition of InnovationRx, we look at Phil Knight’s big cancer gift, Medallion’s credentialing clearinghouse, a ...

In a statement on Tuesday, Viking Therapeutics, Inc. (NASDAQ:VKTX) said that its phase 2 trial for VK2735 tablet saw a ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral Dosing study, which evaluated the safety and efficacy of the oral formulation of ...

The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

Current health news highlights include Viking's weight-loss pill failing to meet financial expectations, European corporate ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...

The system, from Signos, offers three- and six-month plans ($139 and $129 a month, respectively), and the company will send all of the continuous glucose monitors a patient needs, CNBC reported. Plus: ...

A draft copy of an upcoming MAHA report reveals a strategy in lockstep with recent HHS actions such as reviving the Task ...

Viking Therapeutics Inc (NASDAQ: VKTX) reported new clinical data for its oral obesity drug – sending shares sharply lower as ...